GPCR Safety Panels Launched
We are pleased to introduce our new GPCR Safety Panels, designed to help evaluate the off-target potency of candidate compounds in drug discovery and preclinical research. These panels include G-protein coupled receptors (GPCRs) often linked with common adverse reactions, making them practical resources for pharmaceutical R&D. Our standard GPCR Safety Panel features a minimal set of 24 representative GPCRs, allowing for testing compounds in agonistic and antagonistic modes. For broader coverage, the GPCR Safety Panel Premium exhaustively includes 31 additional GPCRs from the same receptor families. The list of the receptors in the panels can be found at the bottom of this page. Several GPCR families are known to cause […]
Core Technology for Our GPCR Functional Assay Patented in Japan
We are pleased to announce that the core technology for our GPCR functional assay has been patented in Japan. The University of Tokyo holds the patent and exclusively licenses it to Tanso Biosciences. G protein-coupled receptors (GPCRs) are proteins that exist on the cell membrane, and there are hundreds of GPCRs in humans. GPCRs regulate various physiological functions and are related to many diseases, so they have been studied as promising drug targets. However, there are problems with existing test methods, such as many challenging receptors and high costs, which have significantly hindered GPCR research. Our founding researchers developed a sensitive and comprehensive GPCR functional assay method, the technology of […]
Interview with Tanso Biosciences CEO by NIKKEI Biotech
At the interview by NIKKEI Biotech, CEO Hideaki Ogasawara talks about Tanso Biosciences' proprietary GPCR functional assay, which surpasses existing methods in sensitivity, comprehensiveness, and cost-effectiveness. [blogcard url="https://bio.nikkeibp.co.jp/atcl/column/16/021500017/031200159/"]
Distributor agreement with Cosmo Bio
Tanso Biosciences, Inc. has entered into a distributor agreement with Cosmo Bio Co., Ltd to provide contract assay services in Japan and contribute to expanding frontiers, accelerating research, and reducing risks of GPCR drug discovery. Its innovative functional assay is reliably sensitive to all the major Gα subtypes, including notoriously intractable G12/13, and opens up opportunities with ~300 GPCRs.
GPCR ranking: Number of receptor-targeted drugs
All GPCRs are not made equal. As illustrated in "About GPCR," some GPCRs have dozens of drugs targeting them while the majority of GPCRs have few or none in the market, clinical trials, or labs. Based on a GPCR drug database [1,2], the figure above and the table below rank GPCRs in ascending and descending order, respectively, of the number of receptor-targeted drugs. The distribution is obviously skewed. N.B., there are also ~150 nonsensory GPCRs missing in the table since they have never been addressed as therapeutic targets. Some drug-receptor pairs have multiple statuses/phases like Approved and Phase 3 in the database [1]. In such cases, the most advanced status […]